Quest Diagnostics (DGX) stock performance was marked by significant events, starting with a 3.1% rise after the previous earnings report. The firm received an upgrade in its stock rating from StockNews.com, confirmed a partnership with Optum, and enacted a deal to acquire PathAI Diagnostics to speed up AI and digital pathology adoption in cancer diagnosis. DGX also announced a collaboration with Broad Clinical Labs, a deal with Lee Health for Lab Services, a launch of MelaNodal Predict™ and an agreement with Instacart to decrease food insecurity. DGX exceeded Q1 2024's earnings and revenue estimates while raising its guidance for the full year 2024. At the same time, DGX faced a few underperformance days compared to competitors and saw stakes sold by BI Asset Management Fondsmaeglerselskab A S and ING Groep NV. Despite the challenges, DGX paid a quarterly cash dividend. Emergence of AI and digital technologies in healthcare, new services and products, strategic partnerships and strong financial results paint a promising picture for Quest Diagnostics.
Quest Diagnostics DGX News Analytics from Thu, 13 Jul 2023 07:00:00 GMT to Sun, 26 May 2024 10:06:30 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor 2
